Ophthalmology

Top Story

Valeant, EyeGate enter licensing agreement

February 21, 2017

Valeant Pharmaceuticals has entered into a licensing agreement with EyeGate Pharmaceuticals regarding the EyeGate II delivery system and EGP-437 combination product candidate for postoperative pain and inflammation, according to a press release from the companies.

Through the agreement, Valeant will have worldwide commercial and manufacturing rights for the EyeGate II delivery system and EGP-437, while EyeGate will maintain development of the delivery system in the U.S. Valeant can develop the system outside of the U.S.

Blog

BLOG: The goblet cell non-controversy

February 21, 2017
One of the neat things about being on the Rubber Chicken Dinner Circuit of industry-sponsored talks is that you get to hear firsthand what it is that your peers are…
Meeting News

Anti-VEGF therapy may not have impact on cataract surgery outcomes in DME patients

February 21, 2017
MIAMI — Anti-VEGF therapy for the treatment of diabetic macular edema does not have a negative impact on patients who undergo cataract surgery, according to a…
Meeting NewsFrom OSN EuropeVideo

VIDEO: Measuring keratoconus progression still challenging

February 21, 2017
MAASTRICHT, Netherlands – At the European Society of Cataract and Refractive Surgeons winter meeting, David Touboul, MD, PhD, speaks about

Glaukos completes enrollment in iStent Supra trial

February 20, 2017
Enrollment in the investigational device exemption trial for the iStent Supra for treatment of patients with open-angle glaucoma and cataracts has been completed…
More News Headlines »
Original Article

Tomographic Findings After Implantation of Ferrara Intrastromal Corneal Ring Segments in Keratoconus

Journal of Refractive Surgery, February 2017, Volume 33 Issue 2
To analyze and compare changes to the anterior and posterior corneal surfaces after Ferrara intracorneal ring segment…
More »
CME

Glaucoma 2017: Controlling IOP and Promoting Adherence through Novel Therapeutics

This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to…
More »
Featured
Hawaiian Eye/Retina Meeting

Hawaiian Eye/Retina Meeting

From OSN Europe Video
Meeting News

VIDEO: Astigmatism affects multifocal IOL models

February 20, 2017
More »
Advertisement
Advertisement